Vector Labs Ab02390-10.3 Anti-CD3e [Visilizumab (HuM291)], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: Visilizumab (HuM291)
Heavy Chain Modification: Fc Silent™
Synonyms: T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3-ε
Amount: 200 μg
Application Codes Clone: FC; Therapeutic; immunesuppression
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody recognises the human CD3 epsilon. This antibody also competes with OKT3 (Muromonab) for binding site on the human T cells suggesting that they bind overlapping or closely spaced epitopes.
Application Notes: This antibody is derived from its a murine parent antibody called M291. HuM291 was significantly less mitogenic to T cells in vitro as compared to OKT3 and induced the release of much lower levels of the cytokines tumor necrosis factor-α, interferon-γ, and interleukin-10. HuM291 still retained the ability to modulate the CD3 complex and inhibit the mixed lymphocyte reaction. This antibody competes with OKT3 for binding to human T cells, which was detected using flow cytometry (PMID: 10480417). In vitro studies using chimpanzee peripheral blood mononuclear cells (PBMCs), HuM291 was reported to be less mitogenic than OKT3 and effectively depleted peripheral T cells without eliciting clinical signs of cytokine release syndrome, and recovered T cells were functionally normal (PMID: 10480415). Phase 1 trial of HuM291 in patients receiving renal allografts suggested that it was well tolerated and rapidly depleted circulating T cells in a dose-dependent manner and was associated with only mild to moderate symptoms of cytokine release (PMID: 11152101). Treatment with visilizumab (HuM291) in severe steroid-refractory ulcerative colitis induced symptomatic response and clinical response (PMID: 19714757). The (99m)Tc labeled version of this antibody is also recommended for imaging of human T cells and study of human T-lymphocyte trafficking and lymphocytic infiltration of tissues and organs (PMID: 19759100). This antibody is also reported to have some activity in advanced glucocorticoid-refractory acute graft-versus-host disease (GVHD) (PMID: 11929757).

Product Class:	Purified
Clone ID:	Visilizumab (HuM291)
Heavy Chain Modification:	Fc Silent™
Synonyms:	T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3-ε
Amount:	200 μg
Application Codes Clone:	FC; Therapeutic; immunesuppression
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody recognises the human CD3 epsilon. This antibody also competes with OKT3 (Muromonab) for binding site on the human T cells suggesting that they bind overlapping or closely spaced epitopes.
Application Notes:	This antibody is derived from its a murine parent antibody called M291. HuM291 was significantly less mitogenic to T cells in vitro as compared to OKT3 and induced the release of much lower levels of the cytokines tumor necrosis factor-α, interferon-γ, and interleukin-10. HuM291 still retained the ability to modulate the CD3 complex and inhibit the mixed lymphocyte reaction. This antibody competes with OKT3 for binding to human T cells, which was detected using flow cytometry (PMID: 10480417). In vitro studies using chimpanzee peripheral blood mononuclear cells (PBMCs), HuM291 was reported to be less mitogenic than OKT3 and effectively depleted peripheral T cells without eliciting clinical signs of cytokine release syndrome, and recovered T cells were functionally normal (PMID: 10480415). Phase 1 trial of HuM291 in patients receiving renal allografts suggested that it was well tolerated and rapidly depleted circulating T cells in a dose-dependent manner and was associated with only mild to moderate symptoms of cytokine release (PMID: 11152101). Treatment with visilizumab (HuM291) in severe steroid-refractory ulcerative colitis induced symptomatic response and clinical response (PMID: 19714757). The (99m)Tc labeled version of this antibody is also recommended for imaging of human T cells and study of human T-lymphocyte trafficking and lymphocytic infiltration of tissues and organs (PMID: 19759100). This antibody is also reported to have some activity in advanced glucocorticoid-refractory acute graft-versus-host disease (GVHD) (PMID: 11929757).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews